Rexulti (brexpiprazole) withdrawal lacks a single clean timeline because no large clinical study has tracked the day-by-day course of stopping this specific drug. What we do know is shaped by Rexulti’s unusually long half-life and by broader research on antipsychotic withdrawal. For most people, the acute phase of withdrawal begins within a few days of the last dose and peaks within one to two weeks, but some individuals report symptoms persisting for months. The variability is wide enough that anyone stopping Rexulti should plan with a prescriber rather than rely on a fixed calendar.
Why Rexulti’s Half-Life Matters
Rexulti has an elimination half-life of about 91 hours, which means the drug lingers in your system for a long time after each dose. Steady-state blood levels take roughly 10 to 12 days to build up when you start the medication, and the reverse is true when you stop: the drug clears slowly, with meaningful amounts still circulating for more than two weeks after your final pill.1Psychopharmacology Bulletin. Brexpiprazole Utilization in Adults and Children–Adolescents: Current Perspectives That built-in taper from the drug’s own slow clearance is one reason Rexulti’s withdrawal onset tends to be more gradual than it is with shorter-acting antipsychotics. You are unlikely to feel full withdrawal effects the day after your last dose the way you might with a drug that clears in hours.
This slow clearance has a practical upside and a practical downside. The upside is that a missed dose or two rarely triggers an immediate crisis, and the initial days after stopping tend to feel manageable. The downside is that withdrawal symptoms can creep in gradually over the first week or two, sometimes making it hard to recognize them as withdrawal at all. People sometimes attribute the emerging discomfort to stress, poor sleep, or a return of their original condition rather than the drug leaving their body.
What Withdrawal Symptoms Actually Look Like
Rexulti acts on dopamine and serotonin receptors, and when the drug is removed, the brain’s recalibration produces a range of effects. Commonly reported symptoms across antipsychotic withdrawal include insomnia, nausea, anxiety, irritability, and restlessness. Some people describe a flu-like state with sweating, headaches, and muscle aches. Mood swings and rebound depression or psychosis can also surface, though separating withdrawal-driven mood changes from a return of the underlying condition is one of the trickiest parts of the process.
Movement-related symptoms deserve special mention. When an antipsychotic is abruptly removed, dopamine receptors that had been blocked can suddenly respond to normal dopamine levels with exaggerated activity. This can produce involuntary movements, a phenomenon sometimes called withdrawal dyskinesia, which involves repetitive, purposeless movements of the face, tongue, or limbs.2PubMed Central. A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse These motor effects are generally temporary when they appear during withdrawal, distinguishing them from tardive dyskinesia, which persists even while on the medication. Still, they can be alarming if you are not expecting them.
Other symptoms that people report less frequently include dizziness, appetite changes, vivid or disturbing dreams, and a sense of depersonalization. The particular mix varies from person to person based on their dose, how long they took the medication, and individual neurobiology.
How Common and How Severe
The best large-scale data on the experience of antipsychotic withdrawal comes from a survey of 585 people who attempted to stop various antipsychotic medications. Of those who had tried to come off their drug and answered questions about withdrawal, about 73% reported experiencing some withdrawal effects.3PubMed Central. The experiences of 585 people when they tried to withdraw from antipsychotic drugs Among those who experienced withdrawal, roughly half described the effects as severe, about 29% called them moderate, and around 19% said they were mild.
That study covered several antipsychotic drugs rather than Rexulti specifically. Interestingly, aripiprazole (Abilify), which is Rexulti’s close pharmacological cousin and another partial dopamine agonist, had the highest rate of withdrawal symptoms at about 82%, significantly more than risperidone at 61% or quetiapine at 68%.3PubMed Central. The experiences of 585 people when they tried to withdraw from antipsychotic drugs This is worth knowing because Rexulti and Abilify share a core mechanism as partial agonists at the D2 dopamine receptor, so Rexulti users may face a similar withdrawal profile. No one has studied this head-to-head, but the family resemblance is reason to take withdrawal planning seriously.
Cold Turkey Versus Gradual Tapering
You might assume that stopping abruptly would always produce the worst withdrawal, and that tapering would reliably make things easier. The relationship turns out to be more complicated than that. In the same survey, people who stopped cold turkey reported withdrawal effects about 61% of the time, with roughly 27% calling the effects severe. People who took a year or more to taper, by contrast, reported withdrawal effects 93% of the time, with about 71% calling them severe.3PubMed Central. The experiences of 585 people when they tried to withdraw from antipsychotic drugs
Before concluding that fast is better, consider the selection bias at work. People who managed to quit cold turkey without intolerable symptoms may have been on lower doses, used the drug for a shorter time, or simply had less severe underlying conditions. People who needed a year or more to taper may have been dealing with higher doses, longer treatment histories, or more challenging withdrawal responses from the outset, which is precisely why they extended the process. The severity of their withdrawal likely drove the slow taper rather than the slow taper creating the severity. What the data does make clear is that tapering is not a guarantee of a smooth ride. Even a careful, extended reduction can involve significant discomfort.
The standard clinical advice remains to taper gradually under a prescriber’s supervision, reducing the dose in small steps rather than halving it or stopping all at once. For Rexulti specifically, doses typically range from 0.5 mg to 4 mg, and prescribers often step down by 0.5 mg or 1 mg at intervals of one to several weeks. The 91-hour half-life gives a natural buffer, but the brain’s receptor systems still need time to readjust at each new dose level.
The Acute Phase and Beyond
Given Rexulti’s slow clearance, a reasonable estimate for the acute withdrawal window is roughly one to four weeks after the final dose. Most physical symptoms like nausea, insomnia, and restlessness tend to peak during this period and then gradually subside. For many people, the worst of it is over within two to three weeks.
But “over” is doing heavy lifting in that sentence. Among those in the antipsychotic withdrawal survey who spontaneously reported how long their symptoms lasted, about a third said two weeks or less, while another third said one to six months. A handful described effects persisting for one to two years, and six respondents reported ongoing symptoms stretching from 15 months to a decade.3PubMed Central. The experiences of 585 people when they tried to withdraw from antipsychotic drugs Those numbers come from a small subset who volunteered the information, so they are not statistically robust, but they illustrate a real phenomenon: for some people, withdrawal from antipsychotics is not a two-week affair.
Protracted withdrawal, sometimes called post-acute withdrawal, involves lingering symptoms that persist well beyond the time needed for the drug to fully leave your body. The symptoms at this stage tend to be more psychological than physical: persistent insomnia, ongoing anxiety, difficulty concentrating, emotional blunting, or mood instability. These effects may reflect the time the brain needs to fully restore its receptor balance after months or years of medication exposure. The process is not well understood, and research specifically tracking Rexulti’s protracted withdrawal course does not exist yet.
Telling Withdrawal Apart from Relapse
This is arguably the most important practical question for anyone stopping Rexulti: is what you are feeling withdrawal, or is your underlying condition returning? The distinction matters enormously because the two call for opposite responses. Withdrawal means your body is adjusting and the discomfort will pass, while relapse means you may need to restart or switch treatment.
A few patterns help separate them, though none is perfectly reliable. Withdrawal symptoms typically appear within days to a couple of weeks after a dose reduction or discontinuation, and they often include physical effects like nausea, sweating, and insomnia that were not features of your original illness. Relapse tends to emerge more gradually and resembles what you experienced before starting the medication. If you had schizophrenia managed with Rexulti, a return of paranoia or hallucinations weeks or months after stopping is more likely relapse. If you experience sudden restlessness, nausea, and headaches within a week of your last dose, that pattern points toward withdrawal.
One underappreciated complication is that withdrawal itself can temporarily worsen psychiatric symptoms. The neurobiological rebound from removing an antipsychotic can include psychotic symptoms or severe mood disturbance that looks identical to relapse but is actually a transient withdrawal effect. Research on antipsychotic tapering has highlighted this problem: when the drug is removed too quickly, the surge in dopaminergic activity from sensitized receptors can produce psychotic-like experiences that resolve once the brain recalibrates.2PubMed Central. A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse The risk is that these withdrawal-induced psychiatric symptoms get misinterpreted as proof that the patient “needs” the medication, leading to reinstatement rather than a slower taper. If you and your prescriber are not aware of this possibility, a withdrawal reaction can look like evidence that stopping was a mistake.
Rexulti for Depression and What the Relapse Data Shows
Rexulti is prescribed for two main conditions: schizophrenia and as an add-on treatment for major depressive disorder that has not responded adequately to antidepressants alone. The withdrawal picture may differ depending on which condition you are treating. For depression specifically, a randomized study tested what happened when people who had stabilized on Rexulti plus an antidepressant were switched to antidepressant plus placebo. About 23% of those kept on Rexulti relapsed, while roughly 21% of those switched to placebo relapsed, a difference that was not statistically meaningful.4Acta Neuropsychiatrica. A double-blind, placebo-controlled, randomised withdrawal study of adjunctive brexpiprazole maintenance treatment for major depressive disorder
That finding is worth sitting with. In this trial, stopping Rexulti while continuing the underlying antidepressant did not increase the rate of depressive relapse compared to staying on it. This does not mean Rexulti was ineffective during the initial treatment phase, but it does suggest that long-term maintenance on Rexulti as an antidepressant add-on may not be necessary for everyone. For someone considering withdrawal, this is reassuring: at least for the depression indication, the fear that stopping will inevitably trigger a depressive relapse is not supported by this particular study’s data. The picture for schizophrenia, where Rexulti is used as a primary treatment rather than an add-on, may be quite different.
The Neurobiology Behind the Discomfort
Understanding why withdrawal happens at all helps explain why the timeline is so variable. When you take Rexulti daily, it partially blocks and partially stimulates dopamine D2 receptors. Over time, the brain compensates by adjusting receptor density and sensitivity. When the drug is removed, those adjusted receptors are suddenly exposed to the brain’s natural dopamine signals without the drug’s modulating influence. The result is a temporary mismatch between receptor sensitivity and dopamine levels.
In the movement-control circuits of the brain, this mismatch can produce the involuntary movements described earlier. In circuits related to mood, motivation, and reward, the same kind of rebound can produce emotional flatness, agitation, or a loss of pleasure in everyday activities. In circuits that regulate sleep and arousal, it can disrupt sleep architecture. The brain will eventually recalibrate, but the process takes weeks to months depending on how much adaptation occurred during treatment.2PubMed Central. A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse Longer treatment at higher doses generally means more adaptation and a longer road back to baseline.
Rexulti also affects serotonin receptors and norepinephrine pathways, which adds further layers of adjustment when the drug is removed. The multi-receptor pharmacology is part of what makes withdrawal from newer antipsychotics unpredictable compared to older drugs that primarily blocked one receptor type.
Factors That Influence Your Personal Timeline
Several variables push withdrawal duration shorter or longer for any given person:
- Duration of use: Someone who took Rexulti for three months has given their brain less time to adapt than someone who took it for five years. Shorter treatment courses generally mean easier withdrawal.
- Dose: Higher doses produce greater receptor adaptation. A person tapering from 4 mg faces a larger neurochemical adjustment than someone coming off 0.5 mg.
- Taper speed: Slower reductions give the brain more time to adjust at each step, potentially reducing the severity of symptoms at any given point, even if the overall withdrawal period stretches out.
- Other medications: If you are also taking an antidepressant, a mood stabilizer, or another psychiatric medication, those drugs may buffer some withdrawal effects or introduce their own complications.
- Individual metabolism: Rexulti is processed by specific liver enzymes, and genetic variation in those enzymes means some people clear the drug faster than others. A faster metabolizer may feel withdrawal effects sooner after stopping.
- Underlying condition: Someone whose original illness was more severe or more biologically driven may have a harder time distinguishing withdrawal from relapse, and the stress of withdrawal itself can destabilize a fragile remission.
Practical Steps for a Safer Withdrawal
If you are considering stopping Rexulti, a few concrete strategies can reduce your risk of a rough withdrawal. First, do not stop abruptly unless a prescriber has told you to for medical reasons, such as a dangerous side effect. Even with Rexulti’s long half-life providing a natural buffer, cold-turkey cessation removes the option of pausing or slowing down if problems emerge.
Work with your prescriber to design a tapering schedule. A common approach is to reduce by the smallest available increment, often 0.5 mg, and hold at each new dose for two to four weeks before the next reduction. If withdrawal symptoms flare at a given step, staying at that dose for longer before reducing again is generally preferable to pushing through or going back up to the previous dose. Some prescribers use liquid formulations or pill-splitting techniques for even smaller reductions near the end of the taper, since the final step from a low dose to zero is often the hardest.
Keep a simple symptom diary during the taper. Track sleep quality, mood, physical symptoms, and any unusual movements. This gives both you and your prescriber data to work with when deciding whether to hold, slow down, or proceed. It also helps with the withdrawal-versus-relapse question, since a diary makes patterns more visible than relying on memory alone.
Be prepared for the possibility that withdrawal will take longer than you hoped. Many people approach medication discontinuation expecting a clean break within a week or two, and feeling ongoing symptoms past that window triggers anxiety about whether something is seriously wrong. Knowing ahead of time that antipsychotic withdrawal can stretch into months for a meaningful minority of people helps frame the experience without panic. If symptoms are manageable but persistent, patience and continued monitoring may be all that is needed. If they are severe or worsening, that is a conversation to have with your prescriber about adjusting the plan.